🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

155 results for “control” Clear

  1. Control Group

    Tvardi Therapeutics

    Squamous Cell Carcinoma of Head and Neck

    phase 1 small molecule terminated

    1 trial

  2. Double-Blind, Randomized, Placebo-Controlled, Phase 1b, Pharmacodynamic Trial of TEV-56192 Following a Single Intravenous Administration in Healthy Participants

    Lacuna Pharma Pty Ltd

    Pruritus

    phase 1 other active

    1 trial

  3. GRT-1C102: A randomized, double-blind, placebo-controlled dose escalation study to evaluate the safety, tolerability, and pharmacokinetics/pharmacodynamics of GRT-001 after subcutaneous administrations to healthy subjects (MONOSqut trial).

    Rani Therapeutics Holdings

    Ulcerative colitis

    phase 1 other active

    1 trial

  4. Open label, Phase I study to assess and compare the pharmacokinetic parameters after multiple oral administration of stiripentol 1000 mg in renal impaired patients and matching controls with normal renal function

    Biocodex

    Patients with renal impairement

    phase 1 other active

    1 trial

  5. Phase 1, Randomized, Double-blind, Placebo-Controlled, First-in-Human Single Ascending Dose Study in Healthy Participants to Assess the Safety, Tolerability, and Pharmacokinetics of JNJ-95597528 and a Proof of Mechanism Study in Participants with Mild to Moderate Asthma

    Janssen-Cilag International N.V.

    Mild to Moderate Asthma

    phase 1 other active

    1 trial

  6. Phase I, single and multiple ascending dose, randomized, double-blind, placebo-controlled, parallel-group clinical trial to evaluate the safety, tolerability and pharmacokinetics of topical ocular administration of DS101 in healthy subjects.

    The George Institute

    Diabetic retinopathy.

    phase 1 other active

    1 trial

  7. Phase I, single and multiple ascending dose, randomized, double-blind, placebo-controlled, parallel-group clinical trial to evaluate the safety, tolerability and pharmacokinetics of topical ocular administration of DS101 in healthy subjects.

    The George Institute

    Diabetic retinopathy.

    phase 1 other active

    1 trial

  8. Phase Ib Randomised, Placebo-controlled, Double-blind, Multicentre Study to Assess the Effects and Safety of AZD5462 on top of Dapagliflozin in Participants with Heart Failure and Moderate Renal Impairment

    AstraZeneca AB

    Moderate Renal Impairment, Heart Failure

    phase 1 other active

    1 trial

  9. Placebo pills for 14-day intervention

    BRIGHT MINDS BIOSCIENCES INC.

    Healthy Controls

    phase 1 small molecule active

    1 trial

  10. Randomized, double-blind, placebo-controlled, two-part study assessing the safety, tolerability and pharmacokinetics of BP1.7881 administered as higher doses, after single ascending doses (Part I) and multiple ascending doses (Part II), including the assessment of BP1.7881 on cardiac repolarization, in healthy subjects.

    Bioprojet Pharma

    Eosinophilic esophagitis

    phase 1 other active

    1 trial

  11. Safety, pharmacokinetics and pharmacodynamics study of Leucettinib-21 in healthy subjects, Down Syndrom and Alzheimer patients

    Lacuna Pharma Pty Ltd

    A Phase 1, Randomized, Double-Blind, Placebo-Controlled, First in Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Ascending Doses and Food Effect of Leucettinib-21 in Healthy Male Subjects, followed by an open single dose of Leucettinib-21 in Down Syndrome individuals, and patients with Alzheimer’s disease

    phase 1 other active

    1 trial

  12. Safety, tolerability, pharmacokinetics, and pharmacodynamics of intravenous and subcutaneous multiple rising doses of BI 765250 versus placebo in trial participants with moderate to severe plaque psoriasis (double-blind, randomised, placebo-controlled, parallel-group design)

    Boehringer Ingelheim

    Plaque psoriasis

    phase 1 other active

    1 trial

  13. TGD001 SAD study in healthy volunteers

    Lacuna Pharma Pty Ltd

    A Phase I randomized, double-blind, placebo-controlled study to assess the safety and pharmacokinetics of single-ascending doses of TGD001 in healthy volunteers

    phase 1 other active

    1 trial

  14. The pivotal bioequivalence study comparing the test product to the reference product, which belong to the group of medicines used in the treatment of type 2 diabetes mellitus when the condition cannot be adequately controlled by diet and exercise alone.

    Lacuna Pharma Pty Ltd

    Not applicable (submitted trial is a BE study in healthy subjects).

    phase 1 other active

    1 trial

  15. This is clinical study to test, for the first time in people, the safety (any good or bad effects), how long the drug can stay in the body and if it can control the disease of people diagnosed with advanced cancer that has not responded to treatment, has returned after it has been treated, or cannot be treated by surgery, drugs, or any other known treatments.

    Celgene Europe Limited

    Part C: advanced or unresectable STs (Spain only), Part B : r/r diffuse large B cell lymphoma (DLBCL) (Cohort 1), advanced basal cell carcinoma (BCC) (Cohort 2), r/r DLBCL under an alternative dosing regimen (Cohort 3), Part A: advanced or unresectable solid tumors (STs) and relapsed and/or refractory (r/r) advanced non-Hodgkin's lymphomas (NHLs)

    phase 1 other active

    1 trial

  16. Two doses of middle-dose recombinant SARS-CoV-2 vaccine (Sf9 Cell) at the schedule of day 0, 28

    Jiangsu Province Centers for Disease Control and Prevention

    COVID-19

    phase 1 mab completed

    1 trial

  17. [11C]OMAR

    BRIGHT MINDS BIOSCIENCES INC.

    Healthy Control

    phase 1 small molecule active

    1 trial

  18. placebo control

    Takeda

    Hemophilia

    phase 1 small molecule terminated

    1 trial

  19. randomized, double-blinded, placebo-controlled

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Prevention of COVID-19 Caused by SARS-CoV-2

    phase 1 mab active

    1 trial

  20. Control: Femoral perineural local anesthetic infusion

    Summit Therapeutics

    Postoperative Pain Following Knee Arthroplasty

    approved small molecule completed

    1 trial

  21. Oxycodone Hydrochloride

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Analgesia, Patient-Controlled

    approved small molecule active

    1 trial

  22. Standard BP control

    The First People's Hospital of Lianyungang

    Hypertension

    approved small molecule active

    1 trial

  23. Xolair 75 mg solution for injection in pre-filled syringe

    Pari Pharma GmbH

    Well controlled severe allergic asthma

    approved small molecule active

    1 trial

  24. a control group

    The First People's Hospital of Lianyungang

    Disorder of Stomach Function and Feeding Problems in Newborn

    approved small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources